For release content, please refer to the attachment.
Recommended Reading
-
COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29,...
Read More -
Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.
Read More